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doi:10.101Easy-to-Read Informed Consent Forms for
Hematopoietic Cell Transplantation Clinical Trials
Ellen M. Denzen,1 Martha E. Burton Santiba~nez,1 Heather Moore,1 Amy Foley,1
Iris D. Gersten,2 Cathy Gurgol,2 Navneet S. Majhail,3,4 Ryan Spellecy,5
Mary M. Horowitz,6 Elizabeth A. Murphy1Informed consent is essential to ethical research and is requisite to participation in clinical research. Yet most
hematopoietic cell transplantation (HCT) informed consent forms (ICFs) are written at reading levels that
are above the ability of the average person in the United States (U.S.). The recent development of ICF tem-
plates by the National Cancer Institute, National Institutes of Health, and the National Heart Blood and Lung
Institute have not resulted in increased patient comprehension of information. Barriers to creating Easy-to-
Read ICFs that meet U.S. federal requirements and pass institutional review board (IRB) review are the result
of multiple interconnected factors. The Blood and Marrow Transplant Clinical Trials Network (BMT CTN)
formed an ad hoc review team to address concerns regarding the overall readability and length of ICFs used
for BMT CTN trials. This paper summarizes recommendations of the review team for the development and
formatting of Easy-to-Read ICFs for HCT multicenter clinical trials, the most novel of which is the use of
a 2-column format. These recommendations intend to guide the ICF writing process, simplify local IRB
review of the ICF, enhance patient comprehension, and improve patient satisfaction. The BMT CTN plans
to evaluate the impact of the Easy-to-Read format compared with the traditional format on the informed
consent process.
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Readability, LegibilityINTRODUCTION
Informed consent is essential to ethical research
and is a required element of participation in clinical
research. The process is an ongoing and dynamic
exchange of information between investigators and
potential participants, guided by a written informed
consent form (ICF). Informed consent is meant to1National Marrow Donor Program, Minneapolis,
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6/j.bbmt.2011.07.022ensure that patients understand the study purpose,
research procedures, risks, and potential benefits, as
well as the voluntary nature of participation so they
can make informed choices [1,2]. The written ICF
summarizes the clinical study and the rights of
research participants, provides a resource for patients
and their families, and serves as documentation of
the patient’s agreement to participate in the study.
In response to concerns that ICFs were becoming
too long, complicated, and difficult to understand, the
National Cancer Institute’s (NCI) Comprehensive
Working Group on Informed Consent in Cancer
Clinical Trials issued its ‘‘Recommendations for the
Development of Informed Consent Documents for
Cancer Clinical Trials’’ [1]. These guidelines were
accompanied by an ICF template that included all of
the basic elements of informed consent, document for-
matting, and sample plain language (hereafter referred
to as Easy-to-Read) recommendations, as required by
federal law (Table 1) [3].
The National Institutes of Health (NIH) and the
National Heart Blood and Lung Institute (NHLBI)
also produced templates to facilitate the use of Easy-
to-Read ICFs in cancer clinical trials. The respective
templates vary in the degree to which each agency183
Table 1. Federally Required Elements of Informed Consent*
1. A statement that the study involves research, an explanation of the
purposes of the research and the expected duration of the subject’s
participation, a description of the procedures to be followed, and
identification of any procedures which are experimental;
2. A description of any reasonably foreseeable risks or discomforts
to the subject;
3. A description of any benefits to the subject or to others which may
reasonably be expected from the research;
4. A disclosure of appropriate alternative procedures or courses of
treatment, if any, that might be advantageous to the subject;
5. A statement describing the extent, if any, to which confidentiality of
records identifying the subject will be maintained;
6. For research involving more than minimal risk, an explanation as to
whether any compensation and an explanation as to whether any medical
treatments are available if injury occurs and, if so, what they consist of, or
where further information may be obtained;
7. An explanation of whom to contact for answers to pertinent questions
about the research and research subjects’ rights, and whom to contact in
the event of a research-related injury to the subject; and
8. A statement that participation is voluntary, refusal to participate will
involve no penalty or loss of benefits to which the subject is otherwise
entitled and the subject may discontinue participation at any time without
penalty or loss of benefits to which the subject is otherwise entitled.
*Taken from the U.S. Department of Health And Human Services
Code of Federal Regulations for the Protection of Human Subjects in Re-
search 45 CFR 116.46 (http://www.cancer.gov/clinicaltrials/understanding/
simplification-of-informed-consent-docs/page4#appendix2).
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readability (outline, language, and tone) and process-
ability (incorporation of explicit information, layout,
mental images, and context clues) [4]. This inconsis-
tency of interpretation makes it challenging for inves-
tigators to create Easy-to-Read ICFs that also meet
federal requirements and pass institutional review
board (IRB) review.
Informed Consent Challenges in
Transplantation
Decisions regarding complex and potentially
curative procedures, such as hematopoietic cell trans-
plantation (HCT), can be particularly challenging for
patients [5]. Stress caused by disease severity, the ur-
gency to move ahead with treatment, and persistent
cognitive effects of chemotherapy and radiation condi-
tioning regimens may reduce patients’ abilities to fully
take in and comprehend the information provided to
them [6-10]. It is important to address these factors
during the informed consent process, because the
literature shows that fully informed patients are more
likely to adhere to the treatment regimen [11,12].
The literature also shows that shortening the length
of the consent form can improve patient understanding
and retention [4,13,14]. In the NCI, NIH, and
NHLBI literature and ICF templates, formal
recommendations on ICF length are not addressed.
We note that length is quite challenging and in a HCT
multicenter clinical trial, required information
regarding patient involvement, risks and side effects
can add great length to a consent form. Inconsistency
among IRBs regarding the required study informationand formatting can also contribute to excessively long
and complicated ICFs [15]. The priority should be given
to legibility and readability recommendations over the
length of the form, because these factors can reduce
the reader’s cognitive effort and improve his or her abil-
ity to locate important information within
the document.
Easy-to-Read Informed Consent Forms
Individuals at all literacy levels prefer and better
understand ICFs written in plain language [16,17].
The use of readability and processability sugges-
tions from the literature has been associated with
improved health outcomes and acceptance of informa-
tion, reduced overall anxiety in patients and have
made the consent document less frightening to the
study participants [4,18,19]. A study by the Eastern
Cooperative Oncology Group found that an Easy-to-
Read ICF was associated with higher patient satisfac-
tion compared with a traditional ICF format [16]. In
addition, higher satisfaction was positively associated
with greater comprehension among patients [16].
We present recommendations for developing
Easy-to-Read ICFs with a 2-column format for
HCT clinical trials, including readability guidelines
to enhance patient comprehension and satisfaction
with the consent process. These recommendations
are intended to: (1) simplify the process for ICF devel-
opment by investigators who write consent forms [1];
(2) reduce the burden associated with review of the
ICF by local IRBs that oversee research projects and
consent forms at their institutions [20]; (3) enhance
the research participant’s understanding of the consent
form [1]; and (4) improve patient satisfaction with the
informed consent process [16].METHODS
The Blood andMarrow Transplant Clinical Trials
Network (BMT CTN) is a national clinical trials net-
work focusing on issues in HCT. It is funded through
2 divisions at the NIH: the NHLBI and the NCI. The
BMT CTN Data Coordinating Center is a collabora-
tion between the Center for International Blood and
Marrow Transplant Research, the National Marrow
Donor Program (NMDP), and the EMMESCorpora-
tion, a contract research organization. The BMT
CTN formed an ad hoc Informed Consent Form Re-
view Team (Team) to address concerns regarding
overall readability and document the length of ICFs
used for BMT CTN trials. The Team included mem-
bers of the Data Coordinating Center, members of the
NMDP Patient Services department and experts in
health services research and biomedical ethics.
Areas of expertise among Teammembers included
IRB participation, research ethics, clinical research,
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lations, health education and patient advocacy. The
objectives were to (1) evaluate the current format of
BMT CTN ICFs for the inclusion of federally re-
quired basic elements for informed consent and
evidence-based readability and processability recom-
mendations; (2) develop an Easy-to-Read ICF tem-
plate that reflects all required basic elements and
readability recommendations for BMT CTN clinical
trials; and (3) issue a formal recommendation for the
development of future BMT CTN ICFs.
The Team performed a literature search on the
topics of adult literacy, patient education and readabil-
ity, informed consent, and pediatric assent develop-
ment. Sources included the NIH Office of Human
Subjects Research, the U.S. Department of Health
and Human Services, the U.S. Department of
Education, the Institute of Medicine, and national
peer-reviewed journals. Sample clinical trial consent
and assent forms from cancer treatment clinics were
also reviewed for completeness, readability, length,
and format.
Based on this review, the Team created an Easy-to-
Read Informed Consent Fact Sheet outlining the rationale
for a proposed novel format. The fact sheet describes 5
elements of recommended readability guidelines for
informed consent forms and was used to update
proposed ICFs for the BMT CTN. The updated
ICFs incorporate the recommended format, which
features a 2-column format reorganized information
sections, and increased spacing between lines of text.
The Team further refined and adapted the new ICFs
through a series of discussions with BMTCTN inves-Table 2. Recommended Readability Guidelines for Informed Cons
Layout
- Use a 2-column format.
- Limit line length to 30-50 characters and spaces; no more than
5 inches of type running horizontally across a page.
- Balance white space with text and graphics.
Organization
- Sequence of information should mirror the reader’s mental
process and concerns.
- Include important information near the beginning of the document.
Typography
- Serif fonts are preferred for text.
- Sans serif fonts are appropriate for section headers.
Plain Language
- Reading level should be 8th grade or lower.
- Paragraphs are short; convey 1 idea per paragraph.
- Sentences are short, simple, and direct.
- Break up long sentences into bulleted lists.
Avoid
- Large blocks of print
- Underlining or italicizing blocks of text
- Stylized initial letters or all capitalstigators, NMDP’s Patient Services and The EMMES
Corporation Clinical Trial Support Services. Feed-
back from research sites and IRBs was also considered
in the process. The recommendations do not address
specialized issues related to genetic testing, bio-
specimen banking, or the Health Insurance Portability
and Accountability Act regulations.RECOMMENDATIONS
The following recommendations provide guidance
for Easy-to-Read ICFs for HCT multicenter clinical
trials. Five elements related to readability and process-
ability are addressed including: layout, organization,
typography, plain language, and ‘‘what to avoid’’
(Table 2). ICF writing teams should first reference
the NCI consent template as the primary document
source [21]. Second, writers should create a standard-
ized outline incorporating the federally required
elements of informed consent and emphasize plain lan-
guage appropriate for HCT clinical trials (Table 1).
Third and last, the writing team should implement
an annual review process to evaluate the most recent
versions of consent templates from the NIH, NCI,
and NHLBI to ensure ICFs from the BMT CTN re-
flect best practices.
Layout
Text layout is an important design factor that af-
fects legibility, reading performance, and information
processing, including the search for specific informa-
tion within a text [22,23]. It generally refers to theent Forms
- Keep headers as close to text as possible.
- Left margins are justified.
- Leave the right margins ragged.
- Leading for body text is approximately 120% of the point size
(1-2 points larger).
- Use simple headers to break up text.
- Use 11-13 point size; text size varies among fonts, even when
the same point size is used.
- Verbs are in active voice.
- Use words that are familiar to the reader.
- Words and terminology are consistent throughout the document.
- Use simple graphics that work with the text, are culturally
relevant, and reproduce well.
- Professional jargon
- Acronyms, symbols, and abbreviations
186 Biol Blood Marrow Transplant 18:183-189, 2012E. M. Denzen et al.presentation of information and graphics on the page,
including spacing between lines (leading) and the
width of columns of text [23]. The lines of text should
be no more than 5 inches running horizontally across
a page (30 to 50 characters and spaces) [23,24].
Recommended leading for body text is approximately
120% of the point size (1-2 points larger) [25]. In ad-
dition, the left margins should be justified and the right
margins should be left ragged. It also is important to
include a generous amount of white space in the doc-
ument to reduce the appearance of clutter, make it
appear more inviting, and to give the reader’s eyes
a rest between sections of text [23]. Addressing legi-
bility concerns within a text can minimize stress and
improve reading performance [22].
The ability to locate information within a text is an
essential consideration in the design and layout of
ICFs. A strategy for locating information in text is
the use of a 2-column format. Compared with reading
comprehension, locating information in text requiresFigure 1. Easy-to-Read 2-column format vs staa series of distinct cognitive operations that are depen-
dent on text features [26]. A 2-column text format is
beneficial to the process of locating information within
a text because readers can more effectively identify tar-
get words [22,24]. Themoderate line widths utilized in
this format shorten the ‘‘jump’’ the eye must make
from the end of 1 line to the beginning of the next
[22,23]. Two-column formatting also helps readers
keep their place as they read and has been established
as more familiar and generally easier to process
[4,22,23]. Newspapers and magazines have used this
format for years because it makes the document
more readable [27]. The 2-column format is a simple
solution for adhering to line length guidelines while
simultaneously shortening the overall length of the
document (Figure 1).
Organization
Proper organization improves document readabil-
ity and processability. Important information, such asndard format for informed consent forms.
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reader, should be near the beginning of the document
[17,28]. Writers should present information in
sections (often referred to as ‘‘chunking’’), introduced
by headers that clearly identify and describe each of
the elements to be discussed, even if the sections
repeat information [29]. Headers should be simple
and spaced close to the related text. Limit lists to 3
to 5 items, because few people can remember more
than 7 independent items [17].
Typography
To improve readability, the Serif fonts (e.g., Gara-
mond, Times New Roman) should be used for body
text. The Serif fonts are generally easier to read because
the tiny strokes (serifs) help the reader’s eyes track hor-
izontally across the line of text [30]. The Sans Serif
fonts (e.g., Arial, Verdana) are appropriate for titles
and headers. These fonts contrast with the font of the
body text and help the title and header stand out on
the page [30]. Printed material should not have more
than 2 font styles on any 1 page [23]. To ensure maxi-
mum readability, use a text size of 11 to 13 points; most
readers can read 12-point text [30]. Text size varies
among fonts even when the same point size is used.
Plain Language
Plain language is communication your audience
can understand the first time they read or hear it [31].
Examples of plain language forHCT specialized termi-
nology are provided in Table 3. There are several
methods for developing written materials in plain lan-
guage. First, write at an 8th grade reading level or lower
[4,14,17,18,23,27,32]. Many word-processing pro-
grams now offer the option to show readability statis-
tics including the Flesch-Kincaid Reading Level and
the proportion of passive sentences. Second, use the ac-
tive voice or ‘‘write the way we talk’’ (Table 3). Third,
repeat the message(s) in the document. This givesTable 3. Plain Language Examples of Hematopoietic Cell Transpla
Specialized Term
Hematopoietic cells Hematopoietic cells are cells that can make bloo
(peripheral blood), or the umbilical cord after
hematopoietic cell transplantation, or HCT.
Allogeneic stem cell
transplantation
An allogeneic transplantation uses blood-making
will replace the abnormal blood cells in the pa
Autologous stem cell
transplantation
An autologous transplantation uses stem cells, o
will replace the abnormal blood cells in the pa
Conditioning regimen A conditioning regimen is a treatment that uses
cells and help donor cells start to grow in you
(or ‘‘conditioning regimen’’) can have a differe
Myeloablative High-intensity treatment is a combination of che
radiation. This is also called ‘‘myeloablative co
Prognosis A prognosis is an idea of how your disease migh
Remission Remission is a stage when you do not have any s
Graft-versus-Host Disease Graft-versus-host disease (GVHD) is a medical c
a common development after allogeneic stem
your tissues after transplantation.the reader multiple opportunities to understand the
message [17,23]. Fourth, use familiar words, provide
sufficient information and organize the content well
[23]. Fifth, include graphics to help make complex
information easier to understand [21]. If the audience
is racially and/or ethnically diverse, use culturally rele-
vant images that are meaningful to them [30]. When
the text is easy to read (written at an 8th grade level
or lower) and is coupled with simple graphics, a stron-
ger message is created because each element helps
explain the other. However, graphics should only be
used when they can be reproduced well and are clear
[23]. Visuals that draw the reader’s eye to important
points are an effective form of emphasis [33]. For exam-
ple, arrows directing the reader to the next page or
a graphic placed alongside core messages help the
reader navigate the document. Sixth, use short, simple,
and direct sentences. Last, break up longer sentences
into bulleted lists to increase white space.Avoid
The reading cues provided by word shapes are lost
with stylized text formats [17]. Such formats include large
blocks of print (too few paragraph breaks), text that is
underlined or italicized, or text in all capitals. Avoid the
unnecessary use of professional jargon, acronyms, sym-
bols, and abbreviations. Shorter words (less than 3 sylla-
bles) are generally easier to understand. If there is not an
appropriate substitute for an unfamiliar term, follow it
with an example using common words [17].
Examples of BMT CTN multicenter clinical trial
ICFs in traditional and Easy-to-Read formats are
available online (S1, S2).DISCUSSION
Each patient’s ability to understand most ICFs and
participate in the decision-making process isntation Specialized Terminology
Plain Language Example
d. These cells are collected from bone marrow, the bloodstream
a baby is born. Transplantation using hematopoietic cells is called
cells from a family member or an unrelated donor. The collected cells
tient.
r blood-making cells, collected from the patient. The collected cells
tient.
a combination of chemotherapy and sometimes radiation to destroy cancer
r bone marrow. Depending on the combination used, each treatment
nt intensity or strength.
motherapy that uses stronger or higher amounts of drugs and sometimes
nditioning.’’
t develop, with or without treatment.
igns or symptoms of disease after treatment.
ondition that can become very serious and may cause death. GVHD is
cell transplant. It happens when the donor cells attack and damage
188 Biol Blood Marrow Transplant 18:183-189, 2012E. M. Denzen et al.influenced by his or her level of health literacy [34]. In
Healthy People 2010, the U.S. Department of Health
and Human Services defined health literacy as ‘‘the de-
gree to which individuals have the capacity to obtain,
process, and understand basic health information and
services needed to make appropriate health decisions’’
[35]. The National Assessment of Adult Literacy
found that 21%ofU.S. adults are functionally illiterate
and an additional 27% have marginal literacy [36,37].
Federal requirements state that information must be
understandable to participants, yet studies indicate
that most oncology ICFs are complicated to the
point that the average person in the United States is
likely to find them difficult to read [38].
Despite efforts to improve the process of informed
consent in cancer research, a significant proportion of
study participants do not fully comprehend the re-
search to which they have consented [39]. Problems
with written ICFs persist because of increasingly com-
plicated protocols that are often randomized to com-
plex treatment arms [40]. Additional challenges are
presented by HCT multicenter clinical trials in which
the procedures, therapies, and possible toxicities are
difficult to explain at the ‘‘layman’’ level [23,40].
Many IRB-approved ICFs are written at a 12th-
grade reading level or higher, although the average
reading ability of U.S. adults is at or below the 8th
grade level [36,40,41].
Well-designed consent forms foster the use
and retention of meaningful information and
enhance the quality of patient–physician interactions
[1,4,13,14,16]. Easy-to-Read ICFs ensure that deci-
sions about medical care are made in a collaborative
manner between patient and physician [42]. The
patient–physician interaction plays a key role in clini-
cal trial enrollment. A study byWright et al. [43] found
that discussions of consent issues between patients and
clinical research associates positively correlated with
the patient’s decision to enter a clinical trial.
Study teams should proactively approach IRBs or
IRB offices to collaborate on effecting changes in
ICFs. IRBs could approve template, layout, and other
suggestions in this paper before individual IRB meet-
ings for more general aspects of the ICF, whereas
study-specific language (specific risks, benefits, goals
of studies, etc.) would be written on a study-by-study
basis. Following this process would reduce the burden
on IRBs while simultaneously increasing consistency
and quality of consent materials. For study teams,
greater uniformity is achieved and they need not worry
about individual IRB boards requiring different
changes to the same text. Finally, all would benefit, in-
cluding research participants, from an ICF that more
effectively conveys information regarding the study.
The Readability Guidelines for ICFs suggested in
this paper will lower the reading level, shorten the doc-
ument length, and improve patient satisfaction inHCT consent documents. The BMTCTN is working
to identify opportunities for educational interventions
among protocol staff and IRBmembers to facilitate the
use of Easy-to-Read ICFs in clinical trials. Educational
interventions may include: samples of both traditional
and Easy-to-Read ICFs, examples of plain language
for specialized terminology, and references from the
literature on improving document readability. BMT
CTN plans to conduct a randomized, controlled trial
to: (1) identify barriers to implementing an Easy-to-
Read ICF in multicenter clinical trials, (2) evaluate
the effectiveness of the 2-column ICF format, and (3)
determine whether the Easy-to-Read ICF lessens
anxiety during the informed consent process. Incorpo-
rating current readability and processability recom-
mendations from the literature will help to improve
ICFs until randomized, controlled trial results are
available [4,18,19].
Future research initiatives should evaluate the
quality of translated Easy-to-Read ICFs. Investigators
may also want to consider multimedia approaches to
improving the informed consent process. However,
a written Easy-to-Read ICF serves as an informational
resource and documents the patient’s agreement to
participate in the study. There is a need for the devel-
opment of templates for consent to genetic testing
and/or the collection of bio-specimens. At this
time, the NCI provides suggested language for bio-
specimen and genetic testing ICFs; no templates exist
for this area of research at the NCI, NIH, or NHLBI.ACKNOWLEDGMENTS
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